

Client: Example Client ABC123

123 Test Drive

Salt Lake City, UT 84108 UNITED STATES

Physician: Doctor, Example

**Patient: Patient, Example** 

**DOB** 1/5/1981 **Sex:** Male

**Patient Identifiers:** 01234567890ABCD, 012345

**Visit Number (FIN):** 01234567890ABCD **Collection Date:** 01/01/2017 12:34

## **Acetylcholine Receptor Modulating Antibody**

ARUP test code 0099521

Acetylcholine Modulating Antibody

66 % H

(Ref Interval: <=45)

Repeated and Verified

INTERPRETIVE INFORMATION: Acetylcholine Modulating Ab

Negative ..... 0-45 percent modulating

Positive ...... 46 percent or greater modulating

Approximately 85-90 percent of patients with myasthenia gravis (MG) express antibodies to the acetylcholine receptor (AChR), which can be divided into binding, blocking, and modulating antibodies. Binding antibody can activate complement and lead to loss of AChR. Blocking antibody may impair binding of acetylcholine to the receptor, leading to poor muscle contraction. Modulating antibody causes receptor endocytosis resulting in loss of AChR expression, which correlates most closely with clinical severity of disease. Approximately 10-15 percent of individuals with confirmed myasthenia gravis have no measurable binding, blocking, or modulating antibodies.

This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the US Food and Drug Administration. This test was performed in a CLIA certified laboratory and is intended for clinical purposes.

VERIFIED/REPORTED DATES				
Procedure	Accession	Collected	Received	Verified/Reported
Acetylcholine Modulating Antibody	22-095-139060	4/5/2022 2:45:00 PM	4/7/2022 9:18:46 AM	4/9/2022 1:55:00 PM

END OF CHART

H=High, L=Low, \*=Abnormal, C=Critical